Evaluation of non-research and research industry payments to pediatric hematologist/oncologists in the United States between 2013 and 2021

Anju Murayama,Hinari Kugo,Sae Kamamoto
DOI: https://doi.org/10.1080/10428194.2024.2317344
2024-02-15
Leukemia & Lymphoma
Abstract:Financial interactions between healthcare industry and pediatric hematologist/oncologists (PHOs) could be conflicts of interest. Nevertheless, little is known about financial relationships between healthcare industry and PHOs. This cross-sectional analysis of the Open Payments Database examined general and research payments to PHOs from healthcare industry in the United States between 2013 and 2021. Payments to the PHOs were analyzed descriptively. Trends in payments were assessed using generalized estimating equation models. Of 2784 PHOs, 2142 (76.9%) PHOs received payments totaling 46.3 million (24.8%) were general payments and $137.7 million (73.5%) were funding for research where PHOs served as principal investigators (associated research funding). Both general payments and associated research funding considerably increased between 2014 and 2019. The number of PHOs receiving general payments and associated research funding annually increased by 2.2% (95% CI: 1.2–3.3%, p  < .001) and 5.0% (95% CI: 3.3–6.8%, p  < .001) between 2014 and 2019, respectively.
oncology,hematology
What problem does this paper attempt to address?